{"schema_version":"1.0","type":"article","title":"After Novartis’ 8,323-Patient Trial Setback, How Should the Cardiovascular Business Case Be Rebuilt?","url":"https://drugnews.com.tw/articles/2026-09-22-pelacarsen-horizon-topline-evidence-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-22-pelacarsen-horizon-topline-evidence-en.md","lang":"en","date":"2026-09-22","publish_at":"2026-09-22T08:00:00+08:00","updated_at":"2026-09-22","category":"商業分析系列","topic":"商業分析系列","tags":["Lp(a)","pelacarsen","HORIZON","Novartis","心血管","臨床試驗"],"summary":"Pelacarsen’s Phase III Lp(a)HORIZON trial enrolled 8,323 patients with established cardiovascular disease and elevated Lp(a). The September 4 initial announcements showed Lp(a) lowering but a missed primary cardiovascular endpoint. This should not be read as an effect precisely equal to zero, nor as a failure of the entire Lp(a) field. The September 4 announcements did not provide full effect estimates, event components, prespecified-population results or complete safety details.","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"Lp(a) reduction is a biomarker change, while the primary cardiovascular endpoint is the clinical outcome; HORIZON lowered the marker but missed the primary endpoint, which should not be interpreted as an effect precisely equal to zero.","url":"https://drugnews.com.tw/assets/articles/pelacarsen-horizon-topline-evidence-en/01_BiomarkerAndOutcomes_en.png"},{"alt":"HORIZON enrolled 8,323 patients with established cardiovascular disease and elevated Lp(a), randomized to pelacarsen or placebo; this is a trial design schematic, not a result distribution.","url":"https://drugnews.com.tw/assets/articles/pelacarsen-horizon-topline-evidence-en/02_TrialDesign_en.png"},{"alt":"What is known is the initial conclusion and the missed primary endpoint; effect size, uncertainty intervals, event components, and complete safety data still require formal presentation.","url":"https://drugnews.com.tw/assets/articles/pelacarsen-horizon-topline-evidence-en/03_KnownAndUnknown_en.png"},{"alt":"The next complete dataset should be read through four lenses: main effect estimate and uncertainty, absolute risk and event components, prespecified populations, and safety plus data completeness.","url":"https://drugnews.com.tw/assets/articles/pelacarsen-horizon-topline-evidence-en/04_NextDataset_en.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/pelacarsen-horizon-topline-evidence-en/01_BiomarkerAndOutcomes_en.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-22）。After Novartis’ 8,323-Patient Trial Setback, How Should the Cardiovascular Business Case Be Rebuilt?。https://drugnews.com.tw/articles/2026-09-22-pelacarsen-horizon-topline-evidence-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-09-22-pelacarsen-horizon-topline-evidence.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}